about
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group studyAn open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016).Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systemsModel-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT.A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic studyGenetic screening reveals a link between Wnt signaling and antitubulin drugs.Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors.Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days.Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.Coronary ectasia in a man on breast cancer therapy presenting with acute coronary syndromeMass spectrometry in the pharmacokinetic studies of anticancer natural products.Influence of drug formulation on OATP1B-mediated transport of paclitaxel.Paclitaxel alters the evoked release of calcitonin gene-related peptide from rat sensory neurons in culture.Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor ELEngineering the assemblies of biomaterial nanocarriers for delivery of multiple theranostic agents with enhanced antitumor efficacy.Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia.Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies.When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6α-hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study.Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).Preparation and Evaluation of Solid-Self-Emulsifying Drug Delivery System Containing Paclitaxel for Lymphatic DeliveryA multi-compartment pharmacokinetic model of the interaction between paclitaxel and doxorubicin
P2860
Q30443910-809475B5-4E37-4AB4-9E53-A1A28496ED77Q33563915-BECAD0FD-C5A6-4601-869D-6AF4B3433FEEQ33611516-7CB505A6-D913-48F6-9C68-3DDFB01D0396Q33749066-E4D4038B-3753-4E78-BE02-39A595001279Q34996710-6AE26DFC-9F5B-4FC1-9A50-39EA5C6DEF73Q35166688-C9413D88-BEFD-4CE0-9846-4FE1B02BB364Q35575497-8D2A2CCF-106E-454C-8154-E7FA88B706A6Q35825630-635B4D9E-9004-4858-957F-662D22F20A7CQ36388079-DBE805CF-86A9-4F1A-B9E5-EDEB701F95BBQ36441268-A0986FC8-2E87-4AAC-81C7-FF8BD05CB941Q36506987-231F8E40-30F7-4D5B-BCE2-C0DC02879A71Q36629864-683D87FD-D17C-48EB-8B75-2899C9C3D1C8Q36695354-2E2B379A-6DAB-49DE-87AB-69E5E103B9E7Q36885663-B5FD4882-0F1C-495A-8EBB-92D04B07FB00Q36940993-06115529-E127-42A6-997C-C5B912615C5EQ36988077-BAAAB91D-6964-4C0F-A26E-90336C8400A7Q37140676-A6A77238-5001-417F-9673-4CEC2FC9816AQ37282649-503C8A9F-15ED-4179-8890-AF528377F3AAQ37319807-0E715701-479F-4BD2-8A69-5518039C2C7DQ38568180-D508BB5D-2A2F-430B-B589-03289F4829ABQ39001980-BA5F1F4C-7107-4F02-BB62-07EB5C3B1D72Q39283600-A51EF08F-0940-47B2-A00F-3CD381D10D9AQ42759005-4D829C43-956A-4141-8082-36A2AB42602CQ45251420-E8591530-A07D-4E22-B212-1050430D5F23Q46811884-7D9DD411-DDEE-438B-AD26-C7E14E0CCCD1Q47721109-7027FBA9-E125-48C5-9BE1-FB2987CC941DQ51460131-A5967BAC-8201-4088-AA65-440BE3367A2AQ52688335-439F349C-AFCC-483C-9842-2E963A245F1DQ52848876-8B8E1C07-53F9-4590-A4B8-DC6B3AAE1013Q59127370-696A90E3-ACAD-449F-9530-A8AD6AE5AC9DQ59323040-CF2E40B4-A341-404E-99A2-104876CC03DF
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Mechanism-based pharmacokinetic model for paclitaxel.
@en
Mechanism-based pharmacokinetic model for paclitaxel.
@nl
type
label
Mechanism-based pharmacokinetic model for paclitaxel.
@en
Mechanism-based pharmacokinetic model for paclitaxel.
@nl
prefLabel
Mechanism-based pharmacokinetic model for paclitaxel.
@en
Mechanism-based pharmacokinetic model for paclitaxel.
@nl
P2093
P1476
Mechanism-based pharmacokinetic model for paclitaxel.
@en
P2093
A Henningsson
A Sparreboom
M O Karlsson
P304
P356
10.1200/JCO.2001.19.20.4065
P407
P577
2001-10-01T00:00:00Z